We are live on ! Find out more
ATOS icon

Atossa Therapeutics
ATOS

6 hedge funds and large institutions have $301K invested in Atossa Therapeutics in 2013 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% less funds holding

Funds holding: 8 → 6 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

69% less capital invested

Capital invested by funds: $972K → $301K (-$671K)

Holders
6
Holders Change
-2
Holders Change %
-25%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
+$52.7K
2
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
+$13.2K
3
TRCT
Tower Research Capital (TRC)
New York
+$13.2K
4
BFA
BlackRock Fund Advisors
California
+$6.58K

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$281K
2
Jane Street
Jane Street
New York
-$128K
3
FANJ
Financial Architects (New Jersey)
New Jersey
-$19K
4
U
UBS
Switzerland
-$6.58K
5
BFEC
Benjamin F. Edwards & Company
Missouri
-$4K

ATOS Hedge Fund Activity: Q4 2013 in Review

6 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q4 2013, worth a combined $301K — down 69% from $972K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ATOS and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $52.7K. The largest seller was Invesco, exiting entirely with an estimated $281K sold.

  • 6 institutional investors held Atossa Therapeutics (ATOS) as of Q4 2013, down from 8 in Q3 2013.
  • Funds reported $301K of Atossa Therapeutics stock for Q4 2013, down 69% quarter-over-quarter.
  • 2 funds opened new Atossa Therapeutics positions in Q4 2013 and 4 closed out, a net change of -2 holders.
  • The largest Atossa Therapeutics buyer in Q4 2013 was Virtu KCG Holdings, an estimated $52.7K added.
  • The largest Atossa Therapeutics seller in Q4 2013 was Invesco, an estimated $281K sold.

Based on aggregated 13F filings for Q4 2013.